Detalhe da pesquisa
1.
Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis.
Lancet
; 392(10150): 821-834, 2018 09 08.
Artigo
Inglês
| MEDLINE | ID: mdl-30215381
2.
ERS/ECDC Statement: European Union standards for tuberculosis care, 2017 update.
Eur Respir J
; 51(5)2018 05.
Artigo
Inglês
| MEDLINE | ID: mdl-29678945
3.
Multidrug-Resistant Tuberculosis Treatment Outcomes in Relation to Treatment and Initial Versus Acquired Second-Line Drug Resistance.
Clin Infect Dis
; 62(4): 418-430, 2016 Feb 15.
Artigo
Inglês
| MEDLINE | ID: mdl-26508515
4.
Decreased Time to Treatment Initiation for Multidrug-Resistant Tuberculosis Patients after Use of Xpert MTB/RIF Test, Latvia.
Emerg Infect Dis
; 22(3): 482-90, 2016 Mar.
Artigo
Inglês
| MEDLINE | ID: mdl-26889608
5.
Building clinical trial capacity to develop a new treatment for multidrug-resistant tuberculosis.
Bull World Health Organ
; 94(2): 147-52, 2016 Feb 01.
Artigo
Inglês
| MEDLINE | ID: mdl-26908964
6.
Genotype and allele frequencies of isoniazid-metabolizing enzymes NAT2 and GSTM1 in Latvian tuberculosis patients.
J Infect Chemother
; 22(7): 472-7, 2016 Jul.
Artigo
Inglês
| MEDLINE | ID: mdl-27236516
7.
Effect of NAT2, GSTM1 and CYP2E1 genetic polymorphisms on plasma concentration of isoniazid and its metabolites in patients with tuberculosis, and the assessment of exposure-response relationships.
Front Pharmacol
; 15: 1332752, 2024.
Artigo
Inglês
| MEDLINE | ID: mdl-38584604
8.
Delamanid for Extensively Drug-Resistant Tuberculosis.
N Engl J Med
; 373(3): 291-2, 2015 Jul 16.
Artigo
Inglês
| MEDLINE | ID: mdl-26176402
9.
Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis.
Eur Respir J
; 41(6): 1393-400, 2013 Jun.
Artigo
Inglês
| MEDLINE | ID: mdl-23018916
10.
The value of effective public tuberculosis treatment: an analysis of opportunity costs associated with multidrug resistant tuberculosis in Latvia.
Cost Eff Resour Alloc
; 11(1): 9, 2013 Apr 17.
Artigo
Inglês
| MEDLINE | ID: mdl-23594422
11.
LC-MS/MS method for simultaneous quantification of the first-line anti-tuberculosis drugs and six primary metabolites in patient plasma: Implications for therapeutic drug monitoring.
J Chromatogr B Analyt Technol Biomed Life Sci
; 1185: 122986, 2021 Nov 15.
Artigo
Inglês
| MEDLINE | ID: mdl-34688197
12.
Efficacy and safety of delamanid in combination with an optimised background regimen for treatment of multidrug-resistant tuberculosis: a multicentre, randomised, double-blind, placebo-controlled, parallel group phase 3 trial.
Lancet Respir Med
; 7(3): 249-259, 2019 03.
Artigo
Inglês
| MEDLINE | ID: mdl-30630778
13.
Drug Susceptibility Patterns in MDR-TB Patients: Challenges for Future Regimen Design. A Cross-Sectional Study.
PLoS One
; 10(11): e0142425, 2015.
Artigo
Inglês
| MEDLINE | ID: mdl-26558611
14.
Building clinical trial capacity to develop a new treatment for multidrug-resistant tuberculosis
Bull. W.H.O. (Print)
; 94(2): 147-152, 2016-2-01.
Artigo
Inglês
| WHOLIS | ID: who-271840